Q-omics provides the consensus-scored CDH20 profile across patient tissues and cancer cell-line models. CDH20 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CDH20 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, CDH20 RNA expression shows 15,914 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRP, and GBM as cancer lineages where CDH20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDH20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDH20 survival associations across molecular data types. CDH20 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDH20 RNA expression–survival associations across cancer types. High CDH20 expression shows unfavorable associations in UVM, but favorable associations in HNSC, LGG, KICH, CHOL and THYM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CDH20 RNA expression.
This table summarizes CDH20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for CDH20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDH20 shows lower tumor expression in KIRP, BRCA, HNSC, KIRC, STAD and KICH. The KIRP box plot shows higher CDH20 RNA expression in normal versus tumor tissue (log2 FC = −0.360, t-test p < 0.001).
This table shows molecular features associated with CDH20 in patient tissues and cancer cell lines. In patient samples, CDH20 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDH20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
